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Summary (max 150 words)
A unique and not exactly known O-mannosyl glycan on α-dystroglycan is essential for interaction with extracellular protein ligands. Defective O-mannosylation leads to muscular-dystrophy dystroglycanopathies. Mutations in the ISPD gene, with uncharacterized function, represent the second most common cause of these disorders. Previous studies suggested that the human ISPD protein regulates O-mannosylation initiation by influencing POMT activity. We showed that neither the cytoplasmic dolichol level nor POMT activity is affected by knocking out ISPD in a cell model. Instead, as shown by determination of the crystal structure, human ISPD has a canonical N-terminal cytidyltransferase domain linked to a C-terminal domain that is absent in cytidyltransferase homologues. Functional studies demonstrated CTP-dependent cytidyltransferase activity towards ribulose-5-phosphate, ribose-5-phosphate and, more efficiently, towards ribitol-5-phosphate. Identity of the CDP-ribitol product was confirmed by LC-QTOF mass spectrometry and 2D NMR-spectroscopy. Our combined results indicate that ISPD produces a novel human CDP-nucleotide sugar that is essential for functional glycosylation of α-dystroglycan.

Highlights (max 4 points, 80 characters including spaces each)
-	ISPD acts independent from POMT activity.
-	Crystallization of ISPD shows an N-terminal cytidyltransferase domain.
-	Most efficient cytidyltransferase activity is shown towards ribitol 5-phosphate.
-	LC-QTOF mass spectrometry and 2D NMR analysis confirm CDP-ribitol identity.

eTOC blurb (max 40 words, highlights).
Riemersma et al. crystalized ISPD and showed that ISPD has cytidyltransferase activity towards pentose phosphate sugars and most efficient towards ribitol 5-phosphate.  The identity of the reaction product CDP-ribitol was confirmed by LC-QTOF mass spectrometry and 2D NMR analysis.

INTRODUCTION
Protein glycosylation is an essential and well-studied post-translational modification that requires the sequential addition of single monosaccharides to form a glycan structure, for which nucleotide- and dolichol-linked sugars serve as donors (). α-Dystroglycan (α-DG, encoded by DAG1) is a glycoprotein with a unique and not yet fully elucidated O-mannose linked glycan that is crucial for binding extracellular ligands, such as laminin in muscle (), and neurexin  ADDIN EN.CITE () and slit  ADDIN EN.CITE () in brain. For synthesis of the functional glycan on α-DG, dolichol-phosphate-mannose (Dol-P-Man), UDP-α-D-N-acetyl glucosamine (UDP-GlcNAc) and UDP-α-D-N-acetyl galactosamine (UDP-GalNAc) are incorporated into a GalNAc-β1,3-GlcNAc-β1,4-Man-Ser/Thr trisaccharide, containing a 6-O-phosphoryl modification on the mannose residue. This rare phosphoryl group is probably bound to an essential and not yet fully elucidated part of the ligand-binding epitope that contains repeating –3-Xylose-α1,3-Glucuronic acid-β1– units  ADDIN EN.CITE () and probably some other sugar residues, requiring the availability of at least UDP-α-D-glucuronic acid and UDP-α-D-xylose donors. Defective α-DG O-mannosylation leads to a group of human disorders, known as dystroglycanopathies, which present with muscular dystrophy, severe brain abnormalities and in some cases eye abnormalities (). These disorders are caused by defects in the DAG1 gene itself  ADDIN EN.CITE (, ), or, in the majority of cases, its glycosylation enzymes (). Thus far, known defects in the synthesis of sugar substrates for α-DG O-mannosylation have been limited to Dol-P-Man caused by mutations in DPM3  ADDIN EN.CITE (), DOLK  ADDIN EN.CITE (), DPM2  ADDIN EN.CITE (), DPM1  ADDIN EN.CITE () and GMPPB  ADDIN EN.CITE ().
Recently, mutations in the isoprenoid synthase domain-containing (ISPD) gene were identified in patients with deficient α-DG O-mannosylation  ADDIN EN.CITE (, ), displaying a very heterogeneous spectrum of phenotypes (Supplementary Table S1). Experiments suggested an influence of ISPD mutations on protein O-mannosyltransferase activity  ADDIN EN.CITE () and an additive effect with dystroglycanopathy genes FKTN and FKRP  ADDIN EN.CITE (). ISPD encodes a protein with high sequence identity to the large glycosyltransferase superfamily-A of nucleotide sugar pyrophosphorylases and glycosyltransferases, which share a conserved Rossmann-like fold structure (). While ISPD homologs in plants, protozoa and some bacteria function to synthesize 4-diphosphocytidyl-2-C-methylerythritol (CDP-ME) from 2-C-methyl-D-erythritol 4-phosphate (MEP) and CTP  ADDIN EN.CITE () as part of the non-mevalonate/MEP pathway of isoprenoid synthesis, this pathway is not present in humans. As such, the functional role of human ISPD (hISPD) remains unknown. Here, we investigated the role of hISPD in the α-DG specific O-mannosylation pathway.

RESULTS
hISPD is not involved in dolichol production and acts independently from POMT activity
Previous research suggested that hISPD could influence POMT activity  ADDIN EN.CITE (), i.e. transfer of the first mannose residue of the O-mannose glycan to Ser/Thr residues of α-DG by using Dol-P-Man as sugar donor. We hypothesized that hIPSD could act downstream on POMT activity by regulating the availability of the sugar donor via influencing dolichol levels. ISPD homologs are involved in het non-mevalonate pathway  ADDIN EN.CITE () and the equivalaent classical mevolanate pathway in human produces dolichol in a tissue specific manner  ADDIN EN.CITE (, ). To investigate this hypothesis, in a haploid HAP1 cell line a frameshift mutation into ISPD was induced by transcription activator-like effector nucleases (TALENs)\o "Jae, 2013 #239" and cytoplasmic dolichol levels were measured using HPLC and mass spectrometry. While both independent clones, each carrying a frameshift mutation in the catalytic domain (Figure 1A), were deficient for IIH6 and laminin binding on western blots (Figure 1B), the measured dolichol levels were not different from HAP1 wild type cells (Figure S1),  indicating that hISPD is not involved the dolichol producing pathway and does not influence POMT activity via this route.

In the previous study POMT activity was measured as described previously  ADDIN EN.CITE () and POMT activity in ISPD-deficient patient fibroblasts (30 – 150 pmol/g/h ) was shown to be comparable with that in POMT1-deficient patient fibroblasts (~100 pmol/g/h). Here we performed a similar POMT assay, following the incorporation of labelled Dol-P-Man to GST-tagged α-DG. In two ISPD-deficient patient cell lines, we found considerable POMT activity (245.3 and 332.0 pmol/g/h) comparable with to a control cell line (190.2 pmol/g/h). In addition, POMT activity obtained for a POMT2-deficient cell line (11.6 pmol/g/h) (Figure 1C) was similarly negative to reported values of < 9 pmol/g/h for POMT1- and POMT2-deficient patient cell lines  ADDIN EN.CITE (). To confirm these observations, we assayed POMT activity in the HAP1 ISPD knockout cell lines. In both clones POMT activity was similar to wild-type HAP1 cells (Figure 1C and Figure S2), indicating that hISPD acts independently from POMT activity in α-DG O-mannosylation. 

hISPD appends a novel domain to its conserved cytidyltransferase core
To provide molecular insight into hISPD properties, we determined the crystal structure of hISPD (residues 43-451), in the unliganded state, to 2.4 Å resolution (Table 1). hISPD features a canonical cytidyltransferase domain (residues 43-265) connected, via a linker helix (residues 266-281), to a domain of no known homology (residues 282-451) (Figure 2A). The cytidyltransferase domain adopts the characteristic Rossmann-like α/β fold among nucleotide sugar pyrophosphorylases, featuring an extended β-arm (residues 185-203) for formation of a homodimer (Figure 2B and C), a solution state consistent with gel filtration studies (Figure S3A). The hISPD cytidyltransferase domain superimposes well (Cα root mean square deviation, r.m.s.d. 1.9-2.7 Å, for 202-230 atomic pairs) with a series of closely related prokaryotic cytidyltransferases and ISPD homologs (Figure 2D and Table S2), with minor structural differences in the α3-β4 loop of the core β-sheet (Figure 2D and Figure S4). 
A number of nucleotide sugar pyrophosphorylases append to their cytidyltransferase core a C-terminal extension which functions as an oligomerization module (Figure S5) or incorporates additional enzyme activities (e.g. Bcs1 reductase). hISPD belongs to this subset of ‘extended’ cytidyltransferases, but both the topology of the C-terminal domain (Figure 2E), as well as its angular orientation relative to the cytidyltransfersase core (Figure S5C), is unprecedented. Built from a central 6-stranded parallel β-sheet flanked by α-helices, this domain also contributes to the hISPD dimerization interface, and indeed dimerizes when expressed alone (Figure S3B). We identified distant structural relatives of the hISPD C-terminal domain in two distinct α/β protein families (DALI server; Table S2), including the seven-stranded NAD(P)(H)-dependent short-chain dehydrogenases/reductases (e.g. keto-acyl reductases, Cα r.m.s.d. of 2.9-3.4 Å over ~130 aa; Figure 2F, top) and five-stranded response regulator proteins involved in bacterial sensing systems (e.g. CheY, Cα r.m.s.d. of 2.2-2.5 Å over ~100 aa; Figure 2F, bottom). Despite the structural homology, there is low conservation at the sequence level and hISPD lacks signature sequence motifs in these protein families (Figure S6).

hISPD is cytosolic and has cytidyltransferase activity
Nucleotide sugar pyrophosphorylases involved in human protein glycosylation are known to be cytosolic. To study the subcellular localization of hISPD, a HEK293 cell line stably expressing C-terminally Myc-His-tagged hISPD under a doxycycline inducible promoter was generated. Immunocytochemical staining showed a diffuse widespread staining pattern suggestive of cytosolic localization (Figure S7). This was confirmed by cell fractionation studies, showing hISPD to be present in the cytosolic fraction after doxycycline induction (Figure 3A).
To determine if hISPD has cytidyltransferase activity, we established a malachite green assay to measure released inorganic pyrophosphate (PPi) levels. Using this assay, a basal level of catalytic activity for recombinant hISPD was observed towards MEP (Figure 3B), a known substrate of bacterial IspD  ADDIN EN.CITE (). Since MEP is not known to exist in humans, we additionally screened several physiological pentose- and hexose-phosphates as potential ligands as well as choline-phosphate (choline-P) and glycerol-phosphate (glycerol-P) (Figure 3B), known to be present as CDP derivatives in humans ().
Considerable cytidyltransferase activity was observed for several pentose-5-phosphates, with the highest levels of released PPi detected using ribose 5-phosphate (ribose-5P) and ribulose 5-phosphate (ribulose-5P), followed by xylulose 5-phosphate, as substrates (Figure 3B). Another pentose sugar, arabinose 5-phosphate, as well as hexose sugars, choline-P and glycerol-P, result in PPi levels comparable to, or below the control. ISPD cytidyltransferase activity is dependent on and specific for the triphosphate CTP, while use of CDP, CMP or other nucleotides result in hardly detectable activity (Figure 3C). Taken together, hISPD has cytidyltransferase activity and can use ribulose-5P and ribose-5P as substrates.

hISPD is able to produce CDP-ribulose, CDP-ribose and CDP-ribitol 
The turnover of ribulose-5P and ribose-5P by hISPD in vitro prompted us to investigate if they form the corresponding products CDP-ribulose and CDP-ribose, as well as if the related ribitol 5-phosphate (ribitol-5P) is a substrate for hISPD leading to CDP-ribitol. To this end, ribulose-5P, ribose-5P or ribitol-5P was incubated with recombinant hISPD overnight, and product formation was analyzed by hydrophilic interaction liquid chromatography (HILIC) HPLC. Here, a single product peak was observed in the ribitol-5P reaction (Figure 3D), which was of higher intensity than those from the ribulose-5P and ribose-5P reactions, in which residual CTP was still present (Figure 3E and F). This result indicates that ribitol-5P is preferred over ribulose-5P or ribose-5P as the hISPD substrate. To check for potential other side reactions of hISPD the three reaction mixtures were further analyzed by HILIC LC-QTOF mass spectrometry and to identify all metabolites produced, Molecular Feature Extraction (MFE) was performed. Analysis of the ribulose-5P and ribose-5P reactions revealed the formation of a single molecular mass ([M-H]- 534.05 m/z) (Table S3), corresponding to the expected products CDP-ribose and CDP-ribulose (535.29 Da, C14H23O15N3P2). For both reactions, the extracted-ion chromatogram (EIC) of m/z 534.29 showed two peaks at 9.7 and 10.25 min retention time, (Figure S8A and B), indicative of the presence of both CDP-ribose and CDP-ribulose by molecular inter-conversion. Indeed, 1H NMR analysis demonstrated the isomerization of ribose-5P into ribulose-5P that is independent from hISPD activity, as shown by the control without hISPD (Figure S8C, D, E and F). This suggests a spontaneous isomerization reaction under the experimental conditions tested. Analysis of the ribitol-5P reaction by HILIC LC-QTOF mass spectrometry showed a [M-H]- molecular mass of 536.07 Da, corresponding to the mass of CDP-ribitol (537.31 Da, C14H25O15N3P2) (Table S3).
To confirm the identity of CDP-ribitol, the reaction product was purified by HILIC HPLC and characterized by 1H-13C HSQC and 2D 1H COSY NMR spectroscopy. NMR spectra of a previously prepared CDP-ribitol sample (Pereira & Brown, 2004) were used as reference (Table S4). Characteristic signals were observed for the ribofuranose and cytidine moieties in CDP, and for the ribitol moiety (Figure 4 and Figure S9). Additionally, the signals at 4.14/4.21 ppm (H5’a/H5’b) and 67.4 ppm (C5’) correspond to a ribofuranose ring covalently-linked with ribitol via a pyrophosphate bond, consistent with reported HSQC spectra of CDP-D-arabinitol  ADDIN EN.CITE () and CDP-D-mannitol  ADDIN EN.CITE (), showing similar ppm values for H5’a/H5’b and C5’. Together, these NMR resonances indicate a pyrophosphate linkage between CDP and ribitol.
Since ribitol-5P appeared to be the best substrate for hISPD cytidyltransferase activity, producing CDP-ribitol, we questioned if ribulose-5P or ribose-5P could be reduced by hIPSD to ribitol-5P prior to generation of CDP-ribitol. A similar mechanism is known for the H. influenzae bcs1 enzyme that contains both reductase and cytidyltransferase activity in the production of bacterial CDP-ribitol. To this end, we incubated hISPD with ribulose-5P or ribose-5P in the presence of reductors NADPH and NADH. However, we did not observe any turnover as measured by absorbance at 340 nm (Figure S10), indicating that hISPD is not able to catalyze this reduction under the conditions tested.

Hotspot of hISPD missense mutations in the cytidyltransferase core
At least 30 disease causing truncating mutations (nonsense, frameshift and deletion mutations) have been reported for the ISPD gene (Table S1). These aberrations terminate the protein before or within the C-terminal domain, the absence of which is likely the cause of the enzyme dysfunction. By contrast, the missense mutations reported to date for ISPD (n=12; Table S1) are clustered in the N-terminal cytidyltransferase domain (Figure 5A and B). To identify important catalytic residues for the hISPD cytidyltransferase activity and to investigate potential effects of these missense mutations, we docked the sugar substrates (ribulose-5P, ribose-5P, ribitol-5P) and nucleotide (CTP) onto the active site (Figure 5C), based on superposition with known cytidyltransferase-ligand complexes (Figure S4B). The pentose sugar substrates of hISPD can fit snugly within a binding cleft lined by a number of polar and charged residues (Arg126, Asp156, Ser211, Gln215, Thr238 and Glu239), which serve to interact and stabilize the pentose hydroxyl groups. This pocket can also accommodate the smaller ligands that are known substrates for ISPD homologues (e.g. MEP, choline-P), but are expected to have less optimized binding interactions because of the shorter chain length. The sugar 5-phosphate moiety, the likely nucleophile in the cytidyltransferase reaction  ADDIN EN.CITE (), can be anchored by the invariant Lys263. 
Modelling of the hISPD-substrate-CTP complex allows us to postulate the molecular effects of the 12 missense mutations (Figure 5B) into (i) ‘catalytic’ substitutions that alter the shape of the active site (p.Met213Arg, p.Thr238Ile) or affect interactions with CTP or sugar substrates (p.Ala53Thr, p.Gly54Ala, p.Arg126His, p.Asp156Asn) (Figure 5D); (ii) ‘misfolding’ substitutions that likely disrupt protein structure and stability e.g. by introducing steric clashes with neighboring residues (p.Ala216Asp and p.Pro149Leu), interfering with the non-polar protein core (p.Tyr226His and p.Tyr226Cys), or introducing a conformationally-constrained proline to the core β-sheet (p.Ala122Pro) (Figure 5D); and (iii) ‘oligomerisation’ substitution, represented solely by the p.Arg205His mutation that localizes in the dimer arm (Figure 5E) and may affect homodimer formation. 

DISCUSSION
Although mutations in ISPD are the second most common cause of dystroglycanopathies  ADDIN EN.CITE (, ), until now the function of the hISPD protein in α-DG O-mannosylation is unknown. This study determines the 3-dimensional structure of hISPD, identifies its cytidyltransferase activity towards pentose phosphate sugars, and proposes a role of hISPD in a novel metabolic pathway for nucleotide sugar synthesis.

Involvement of hISPD in α-dystroglycan O-mannosylation
We investigated a proposed scenario  ADDIN EN.CITE () by which hISPD could influence α-DG O-mannosylation via modulation of POMT1/POMT2 activity. However, our results indicate that ISPD neither influences POMT activity via cytoplasmic dolichol levels, nor directly, as shown both with patient fibroblasts and the well-defined HAP1 ISPD knockout system. In stead, our investigations into hISPD led to the findings that it is a cytoplasmic cytidyltransferase which uses CTP as its preferred nucleotide. While hISPD demonstrated no activity against any hexose sugar tested, it is active with pentoses, especially ribulose-5P and ribose-5P. Interestingly, the most efficient substrate we found was ribitol-5P. We therefore investigated the potential of hISPD to catalyze the reduction of ribulose-5P or ribose-5P to ribitol-5P, analogous to cytidyltransferases in the bacteria H. influenza, S. pneumonia and S. aureus, which couple their cytidyltranserase activity with NAD(P)H-dependent reductase activity either in a single enzyme (bcs1) or in two different enzymes (tarI and tarJ)  ADDIN EN.CITE (, , ). The lack of NAD(P)H consumption in our study suggests that this is not the case, in line with the absence of a dinucleotide binding motif in the hISPD C-terminal domain despite its weak structural homology with members of the short chain dehydrogenases/reductases. As a possible explanation, an alternative reductase could act on one or both substrates prior to or after cytidyltransfer, allowing production of CDP-ribitol. 
Until now, CDP-ribitol has not been shown to be present in humans. In the synthesis of pneumococcal and H. influenzae polysaccharides, CDP-ribitol is used as a precursor for the integration of ribitol-P  ADDIN EN.CITE (). By analogy, in humans CDP-ribitol may be incorporated as ribitol or ribitol-phosphate in the laminin-binding epitope of α-DG at an attachment point yet to be elucidated. This will require the transfer of CDP-ribitol to the Golgi apparatus via a nucleotide sugar transporter. The CMP-sialic acid transporter SLC35A1 was identified in a genome-wide screen to be essential for α-DG O-mannosylation  ADDIN EN.CITE (), although sialic acid itself is not part of the laminin-binding epitope (). We recently showed that SLC35A1, but not sialic acid is required for α-DG O-mannosylation  ADDIN EN.CITE (). This opens the possibility of transfer of another nucleotide sugar, such as CDP-ribitol by SLC35A1. It will be of interest to investigate whether the dystroglycanopathy-associated Golgi proteins FKTN and FKRP, belonging to the LicD type of glycosyltransferases with uncharacterized substrates, are involved in the incorporation of ribitol in α-DG. In the bacterium Prevotella tannerae, a protein (ZP_05736246) containing both an IspD and a LicD domain is present and a previous study in zebrafish showed a cooperative interaction between ispd and fktn, and between ispd and fkrp  ADDIN EN.CITE (). 

Homology with crystal structures of other cytidyltransferases
The N-terminal domain of hISPD shows strong sequence and structural homology with known cytidyltransferases, corresponding to its activity towards pentose phosphates, and pointing to an evolutionarily conserved mechanism of protein-substrate interaction as well as cytidyl transfer. Recent efforts were made to develop small molecule inhibitors that target microbial or parasitic ISPDs as potential anti-bacterial, anti-malarial or herbicidal treatment  ADDIN EN.CITE (), with the rationale that these enzymes, part of the non-mevalonate/MEP pathway of isoprenoid synthesis, are absent in humans. The discovery of disease mutations and cytidyltransferase activity for hISPD, coupled with its high homology across the phyla, however, raises the question of its validity as a drug discovery target.
It remains to be determined whether the C-terminal domain of hISPD is endowed with an as yet undetected enzymatic activity, or merely functions in enhancing the stability, activity and integrity of the N-terminal cytidyltransferase domain. Consistent with the latter, we observed that a construct encompassing the hISPD cytidyltransferase domain alone is poorly soluble both in E. coli and Sf9 insect cells. While pathogenic missense mutations are localized only to the N-terminal cytidyltransfersase domain, many of which disrupt the active site integrity, the C-terminal domain, by contrast, harbors a number of truncating aberrations (e.g. premature termination, frameshift or deletion mutations) that lead to reduced cytidyltransferase activity and disease, further suggesting the potential importance of the C-terminal domain towards hISPD function. The limited number of patients identified with ISPD mutations, most of which are compound heterozygous, has thus far hindered a determination of a genotype-phenotype relationship, however, a few inferences can be made. Homozygosity for p.Gly54Ala in one patient lead to a mild phenotype, while homozygosity for p.Asp156Asn in another case gave rise to a severe phenotype. It is possible, then, that Gly54 has a less important role in substrate binding, or that the specific p.Asp156Asn substitution has a more severe effect on the catalytic domain than p.Gly54Ala. Additionally, the most common mutation identified thus far, c.1114_1116del (p.Val372del) found in 5 patients, results in a missing residue in the C-terminal domain but a mild phenotype. Unlike larger deletions or truncations in the C-terminus (e.g. p.Glu396*; deletion of exon 9 and 10) which cause a more severe phenotype when homozygous, this mutation may result in only minor destabilization of the C-terminal domain, allowing it to partially fulfill its function.

Although the majority of genes required for α-DG O-mannosylation seem to have been uncovered, a complete picture of the O-mannose glycan structure and its underlying synthetic pathways still eludes us. Here, we add a new piece to the puzzle by showing that hISPD, in contrast to most dystroglycanopathy gene products in the ER and Golgi, acts in the cytosol to produce a novel CDP-nucleotide sugar that is important and specific for proper α-DG O-mannosylation. Future identification of additional enzymes involved in sugar metabolism may help to establish the exact position of hISPD in the O-mannosylation pathway.

Significance (max 300 words, without citations)




Generation of ISPD knockout cell lines using TALEN technology
HAP1 cells  ADDIN EN.CITE () were cultured in Iscove’s modified Dulbecco’s medium (IMDM, Gibco) supplemented with 10% Fetal Bovine Serum and 1% Penicillin/streptomycin/L-glutamine (Gibco) at 37 °C under 5% CO2 atmosphere. HAP1 ISPD knockout cells were generated using TALEN technology as described  ADDIN EN.CITE (). Used target sequences: 5’TGGCAGAAGATCAGATCAAC-3’ and 5’GAAGTAGTGATTATCCATGA-3’. Sanger sequencing was performed to verify the TALEN plasmid induced mutations. 

Immunoblotting and laminin overlay
SDS-PAGE was performed using 5% or 8% polyacrylamide gels and subsequently proteins were transferred to a nitrocellulose membrane by western blotting. Membranes were incubated with primary and secondary antibodies as detailed in Supplemental Experimental Procedures. A laminin overlay was performed as described  ADDIN EN.CITE (, ). 

Measurement of dolichol levels
A total of 24 3 106 HAP1 cells (wild-type and two ISPD knockout cell lines) were pelleted and used for extraction followed by HPLC-UV as described in the Supplemental Experimental Procedures.

POMT enzyme activity
Fibroblasts of two ISPD-deficient patients (ISPD1: c.832A>T, p.K278* and ISPD2: c.614G>A, p.R205H), control fibroblasts and fibroblasts of a POMT2-deficient patient (c.220del, p.D734fs) and HAP1 control and HAP1 ISPD knockout cell lines (#1 and #2) were pelleted (4 x 107 fibroblasts and 9 x 107 HAP1 cells) for assaying POMT activity as described previously  ADDIN EN.CITE (, ) and in protocol provided in Supplemental Experimental Procedures.

Expression and purification of recombinant hISPD in Sf9 cells
To express sufficient quantity of recombinant protein for crystallization, a DNA fragment encoding an N-terminal truncation (hISPDΔN, residues 43-451) of hISPD was subcloned into a pFB-Lic-Bse vector (GenBank accession number EF199842), in frame with an N-terminal His6-tag and a TEV protease cleavage site. Protein was expressed in Sf9 insect cells and purified to homogeneity by affinity and size exclusion chromatography, followed by His-tag removal. 

Expression and purification of recombinant hISPD in E. coli
To express recombinant hISPD for the enzymatic assay, DNA fragments containing full-length (residues 1-451) or C-terminal domain alone (residues 283-451) were sub-cloned into the pNIC28-Bsa4 vector (GenBank accession EF198106) incorporating an N-terminal TEV-cleavable His6-tag. The plasmids were transformed into E. coli BL21(DE3)-R3-pRARE2, grown in 12 L TB medium with induction by 0.1 mM IPTG overnight at 18 °C and purified as described for the Sf9 cells-expressed protein. 

Crystallographic studies of hISPD
Crystals of hISPDΔN were grown by vapor diffusion at 20 °C from sitting drops of 75 nl protein (15 mg/ml, hISPDΔN, purified from Sf9 cells) and 75 nl reservoir solution containing 25% (v/v) PEG3350 and 0.1 M Bis-Tris pH 6.5. Crystals were mounted in the presence of 25% (v/v) ethylene glycol and flash-cooled in liquid nitrogen. Diffraction data were collected at the Diamond Light Source beamline I03, and processed using MOSFLM and SCALA (). The structure was solved by molecular replacement with PHENIX  ADDIN EN.CITE (), using PDB code 3Q80 as the starting model. Iterative cycles of restrained refinement and manual model building were performed using COOT () and REFMAC5 (). Residues 55-60, 319-334 and 345-347 are disordered in the electron density map, and not modeled in the final model. Crystallographic statistics are in Table 1. Structure analysis and generation of Figures 4 and 5 were performed in ICM-Pro (Molsoft, San Diego).

Generation of a HEK293 hISPD overexpressing cell line
Full-lentgh ISPD mRNA (Gen Bank NM_001101426) was obtained from a Myc-DDK-tagged hISPD ORF clone (OriGene) and the coding sequence was cloned in a pcDNATM5/FRT/TO based expression vector containing a C-terminal-Myc-His tag using the Gateway system (Invitrogen). Generation of a stable T-REx™ Flp-In™ HEK293 cell line and overexpression of hISPD was performed using the hISPD-mycHis tagged construct according to manufacturer’s instructions (Invitrogen). Cells from a confluent 175 cm2 flask were used for cell fractionation as described (). 

hISPD enzyme reactions
The hISPD enzyme assay and subsequent malachite green assay were performed as described  ADDIN EN.CITE (, ), with minor adaptations. Larger scale enzyme reactions were performed for HILIC HPLC and LC-QTOF mass spectrometry and NMR analysis. Detailed protocol is described in Supplemental Experimental Procedures.

NMR analysis
NMR spectra were recorded using a Bruker 500 MHz Avance I or a Varian Unity 800 MHz NMR spectrometer at 298K. For calibration of 1D 1H spectra, the chemical shift of trimethylsilyl propionic acid (TSP) was set at 0.00 ppm. For calibration of 1H-13C HSQC and 2D 1H COSY NMR spectra, the chemical shift was calibrated using the water resonance at 4.7 ppm. NMR spectra were analyzed using Bruker (1D) and Varian (2D) software. 

ACCESION NUMBER
Atomic coordinates and structure factors have been deposited with the PDB under the accession code 4CVH.
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Table 1: Data collection and refinement statistics for hISPD structure.


Data collection and processing
Beamline	Diamond I03 
Wavelength (Å)	0.9795
a,b,c (Å)	79.36, 116.8, 111.8
α=β=γ (°)	90
Space group	C2221










Wilson B factor (Å2)	41.0
R.m.s.d. bond length (Å)	0.0081




Figure 1: POMT activity in ISPD knockout cells and fibroblasts. (A) ISPD locus and genomic DNA sequence of HAP1 cells carrying a TALEN-induced mutation in exon 2 of ISPD that leads to a premature stopcodon. TALEN-recognition sites are highlighted in red and blue. (B) Laminin overlay (LO) assay and IIH6 staining of HAP1 ISPD knockout cells. β-dystroglycan (β-DG) immunostaining was used as a control to asses protein loading. (C) POMT activity in ISPD- and POMT2-deficient patient fibroblasts and HAP1 ISPD knockout cells. n=2, error bars show standard deviation.

Figure 2: Crystal structure of hISPD. (A) Domain organization of hISPD showing the N-terminal cytidyltransferase domain (yellow) dimerization arm (pink), C-terminal domain (green), and inter-domain linker helix (blue). The full-length protein (FL), produced in E. coli, and an N-terminal truncation construct (ΔN), produced in Sf9 cells, were used for enzymatic studies. (B) Structure of the hISPD protomer, colored as in A. Dotted lines indicate disordered regions that are not modelled in the structure. (C) Homodimer of hISPD as seen in the crystal between a protomer (chain A) and its dyad-related subunit (chain A’). (D) Superposition of hISPD N-terminal cytidyltransferase domain with T. maritima IspD (PDB code 1vpa), S. pneumoniae TarI (2vsi) and E. coli IspD (1ini). (E) Structural topology of hISPD C-terminal domain. (F) Structural superposition of hISPD C-terminal domain with representative examples from short-chain dehydrogenases/reductases (e.g. enoyl ACP reductase, top) and response regulator proteins (CheY, bottom). * indicates the additional β-strand in enoyl ACP reductase not found in hISPD (top) and the additional β-strand in hISPD not found in CheY (bottom).

Figure 3: hISPD localization and enzyme reaction. (A) Subcellular fractionation of HEK293 cells overexpressing Myc-His tagged hISPD under an inducible promoter. +: overexpression induced by doxycycline; -: control without doxycycline. Antibodies against cytosolic (HSP90), ER (calnexin) and mitochondrial (ATP5H) proteins were used as a control for the cellular fractionation. (B-C) Cytidyltransferase activity of recombinant full-length hISPD (residues 1-451, produced in E. coli) as measured by formation of inorganic phosphate. Control: incubation without phosphosugar substrate. Data are shown for different phosphosugar substrates (B) and different nucleotides using ribose-5P as substrate (C). Each condition was carried out at least twice. (D-F) Enzyme activity of recombinant hISPDΔN (residues 43-451, produced in Sf9 cells) measured by HILIC HPLC, using ribitol-P 5 (D), ribulose-5P (E) or ribose-5P (F) as substrate. 

Figure 4: 1H-13C HSQC NMR spectrum of CDP-ribitol. 1H-13C HSQC NMR spectrum of HILIC HPLC-purified CDP-ribitol with the 1H NMR spectrum on the top horizontal axis. Numbers refer to the carbon and proton resonances of the cytidine (C5), ribose (C1’-C5’) and ribitol (C1”-C5”) moieties. 

Figure 5: hISPD missense mutations localize in the N-terminal cytidyltransferase core. (A) Domain organization of hISPD showing locations of reported missense mutations. (B) Missense mutation sites mapped onto the hISPD monomer. For B, D and E, the mutation sites are colored in blue for those that could affect catalysis/substrate binding, red for those that could affect folding/stability and purple for the R205H mutation in the dimer arm. (C) Surface representation of the hISPD active site colored on a scale of sequence conservation. Residues that line the binding pockets for sugar substrate (docked with ribulose-5P, Ru5P) and nucleotide (docked with CTP) are shown as sticks. * indicate residues reported to be mutated in patients. (D) View of the hISPD active site showing missense mutation sites (red and blue lines) and other residues (E239, S211, Q215, K263) that are part of the sugar-binding cleft as described in the text (black lines). (E) View of hISPD missense mutation sites with the dimeric subunit shown (surface representation). Residue 205 in the dimer arm, site of the R205H mutation, is highlighted in purple.



